ME01826B - Monoclonal antibodies against amyloid beta protein and uses thereof - Google Patents

Description

"(12) PATENT FILE<br /> 1 <br />me<br />B 01826 ME<br />(11)<br />ME 01826B (19) Montenegro<br />(21) Application number : P-2014-38<br />(22) Date of application submission: 30/11/2006<br />(45) Date of patent publication: 20/12/2014<br /> Gazette : 16/2014<br / > (51) International Classification of ICM<br />C07K16/18<br />2006.01<br />A61K39/395<br />2006.01<br />G01N33/53<br />2006.01<br />G01N33/ 577<br />2006.01<br />C12N15/13<br />2006.01<br />C12N5/18<br />2006.01<br />A61P25/28<br />2006.01<br />(30) Me international right of priority<br />/ US / 740866P 30. 11. 2005<br />/ US / 778950P 03. 03. 2006<br />(65) Number of previously published patent:<br />P-2014/0180 RS<br />(96) Number and date of European patent application:<br />/ EP / 06838873.5 30 November 2006<br />(86) Number and date of international application:<br />/ US / PCT /US2006/046148 11/30/2006<br />(73) Patent Holder<br />, AbbVie Inc.<br />, 1 North Waukegan Road , North Chicago, IL 60064 , US<br />, AbbVie Deutschland GmbH & Co KG<br />, Max-Planck-Ring 2a , 65205 Wiesbaden , DE<br />(74) Representative:<br />, LUTOVAC, Branislav<br />, Bulevar Ivana Crnojevi ca 93 , 81000 Podgorica , ME<br />(72) Inventions c<br />, LABKOVSKY, Boris<br />, 115 Union Road, P.O. Box 7 , Wales, MA 01081 , US<br />, BARGHORN, Stefan<br />, Berliner Strasse 30 , 68161 Mannheim , DE<br />, HILLEN, Heinz<br />, Max-Planck-str. 17 , D-67454 Hassloch , DE<br />, EBERT, Ulrich<br />, Koenigstuhlstr. 6 , D-68163 Manheim , DE<br />, STRIEBINGER, Andreas R.<br />, Ziegelofenweg 46A , 67346 Speyer , DE<br />, KELLER, Patrick<br />, Liebfrauenstr.78 , 64289 Darmstadt , DE<br />(54) Name:<br />me<br />MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN l THEIR USES<br />en<br />MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF"

Claims (16)

1. A monoclonal antibody consisting of a variable heavy chain and a light chain, wherein three CDRs of said variable heavy chain are SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, and three CDRs of said variable light chain are SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, wherein the antibody binds with greater specificity to the amyloid beta protein globulomer than to the amyloid beta protein monomer. 2. The monoclonal antibody according to claim 1, which is a humanized antibody. 3. The monoclonal antibody according to claim 1, wherein the variable heavy chain comprises SEQ ID NO:3 and the variable light chain comprises SEQ ID NO:4. 4. The humanized antibody of claim 2, wherein all or substantially all of the framework regions correspond to those of the human immunoglobulin consensus sequence. 5. A hybridoma that has the assigned number American Type Culture Collection PTA-7238. 6. Monoclonal antibody (8F5) obtained from the hybridoma mentioned in claim 5. 7. The antibody according to any of claims 1-4, or 6 for use in the treatment or prevention of Alzheimer's disease. 8. Pharmaceutical composition containing an antibody according to any of claims 1-4 or 6. 9. A vaccine containing an antibody according to any of claims 1-4, or 6 and a pharmaceutically acceptable adjuvant. 10. Use of antibodies according to any of claims 1-4, or 6 in the production of a drug for the treatment or prevention of Alzheimer's disease. 11. The procedure for diagnosing Alzheimer's disease in a patient who is suspected of having this disease, which includes: a) bringing the biological sample of said patient into contact with the antibody according to any of the requirements 1-4, or 6 in the course of time and under conditions sufficient to antigen/antibody complexes are formed; and b) detecting the presence of said antigen/antibody complexes in said sample, and the presence of these complexes indicates a diagnosis of Alzheimer's disease in said patient. 12. The procedure for diagnosing Alzheimer's disease in a patient who is suspected of having this disease, which includes the steps: a) bringing the biological sample of the mentioned patient into contact with the antigen, which is a globulomer of the amyloid beta (Alš) protein, over time and under conditions sufficient to form antigen/antibody complexes; b) adding the conjugate to the obtained antibody/antigen complexes over time and under conditions sufficient to allow said conjugate to bind to the bound antibody, where said conjugate contains the antibody according to any of claims 1-4, or 6; bound to the compound that gives a signal capable of generating a detectable signal, c) detecting the presence of said antigen/antibody complexes in said sample by detecting the signal generated by said signal-giving compound, and the presence of the complex indicates a diagnosis of Alzheimer's disease in said patient. 13. A method of diagnosing Alzheimer's disease in a patient suspected of having this disease, comprising the steps of: a) contacting a biological sample of said patient with an anti-antibody, where said anti-antibody is specific for said antibody according to any of the claims 1-4, or 6 over time and under conditions sufficient to enable the formation of anti-antibody/antibody complexes, and said complexes contain an antibody present in said biological sample; b) adding the conjugate to the resulting anti-antibody/antibody complexes over time and under conditions sufficient to enable said conjugate to bind to the bound antibody, wherein said conjugate comprises an antigen, which binds to a signal-giving compound capable of generating detectable signal; and c) detecting the signal generated by the signal generating compound, said signal being indicative of a diagnosis of Alzheimer's disease. 14. A method of identifying compounds suitable for active immunization of a patient predicted to develop Alzheimer's disease, comprising the steps of: a) exposing one or more compounds of interest to an antibody according to any of claims 1-4, or 6 over time and under conditions sufficient to said one or more compounds bind to said antibody according to any one of claims 1-4, or 6; and b) identifying these compounds which bind to said antibody according to any one of claims 1-4, or 6, said identified compounds can be used in active immunization in a patient predicted to develop Alzheimer's disease. 15. A kit containing: a) an antibody according to any one of claims 1-4, or 6 and b) a conjugate containing a second antibody specific for Als globulomer bound to a signal-generating compound that is capable of generating a detectable signal, when said second antibody of said the conjugate is different from the antibody according to any of claims 1-4, or 6. 16. A kit comprising: a) an anti-antibody to an antibody according to any one of claims 1-4, or 6 and b) a conjugate comprising a protein A(J) globulomer bound to a signal-giving compound which is capable of generating a detectable signal.